Cite
HARVARD Citation
Gelevski, D. et al. (2023). Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol. Muscle & nerve. 67 (5), pp. 354-362. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gelevski, D. et al. (2023). Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol. Muscle & nerve. 67 (5), pp. 354-362. [Online].